C

CVS Health Corporation (CVS)

NYQ – Real vaqt narxi. Valyuta: USD

95.15

+2.93 (3.18%)

Yopilishda: May 12, 2026, 4:00 PM EDT

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Barcha huquqlar himoyalangan.

Foydalanish shartlari

C

CVS Health Corporation (CVS)

NYQ – Real vaqt narxi. Valyuta: USD

95.15

+2.93 (3.18%)

Yopilishda: May 12, 2026, 4:00 PM EDT

12.05.2026

CVS Health (CVS) is a Top-Ranked Growth Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

11.05.2026

Here's Why CVS Health (CVS) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

11.05.2026

CVS Health: Still Cheap And Signs Of Improvement

CVS Health Corporation remains deeply undervalued despite persistent headwinds and an 11-year correction, with intrinsic value estimates well above current prices. Q1 2026 results showed 6.2% revenue growth and a 63.1% EPS increase, prompting management to raise full-year guidance for revenue, cash flow, and earnings. Margins and the medical benefit ratio are showing early signs of recovery, supporting management's and analysts' renewed optimism for double-digit EPS growth.

10.05.2026

CVS Health Q1 Earnings Call Highlights

CVS Health NYSE: CVS raised its full-year 2026 adjusted earnings outlook after reporting stronger first-quarter results, with management citing improved performance at Aetna, continued execution at Caremark and resilient pharmacy operations.

08.05.2026

CVS Health: Rapidly Improving Metrics And Promising Recovery Deserve Reiterated Buy Rating

The +2.48% YoY payment hike for 2027 Medicare Advantage plans and Aetna's higher star rating support CVS Health's recovery prospects toward 2028 target margins. This is significantly aided by the prior premium re-pricing and the ongoing operational efficiencies, as observed in their FQ1 '26 MBR of 84.6% nearing 2019 levels. Readers must not forget their vertically integrated PBM and pharmacy capabilities, allowing them to drive lower medical costs and improved operational efficiencies.

07.05.2026

These Analysts Increase Their Forecasts On CVS Health After Strong Q1 Results

CVS Health Corp. (NYSE:CVS) on Wednesday posted upbeat first-quarter earnings and issued strong 2026 guidance.

07.05.2026

CVS Health Q1 Earnings: We're (Finally) Back In Buy Territory

CVS Health Corporation delivered a strong Q1, with revenues of $100.4bn and adjusted EPS up ~14% to $2.57, surpassing expectations. CVS raised 2026 guidance: revenue to $405bn, adjusted EPS to $7.4, and cash flow from operations to $9.5bn, reflecting renewed operational momentum. Improvement in the medical benefit ratio to 84.6% and robust health insurance segment profitability signal a turnaround in CVS's core business.

Videolar

30.04.2026

Positive

The Big 3: COST, CVS & MPC

03.03.2026

Positive

SVP & GM of ServiceNow (NOW) on Moveworks, CVS & AI Future

Press-relizlar

06.05.2026

CVS HEALTH CORPORATION REPORTS STRONG FIRST QUARTER 2026 RESULTS AND RAISES FULL-YEAR 2026 GUIDANCE

First quarter total revenues increased to $100.4 billion, up 6.2% year-over-year First quarter GAAP diluted EPS of $2.30 and Adjusted EPS of $2.57 Raising full-year 2026 guidance: GAAP diluted EPS guidance range to $6.24 to $6.44 from $5.94 to $6.14 Adjusted EPS guidance range to $7.30 to $7.50 from $7.00 to $7.20 Cash flow from operations guidance to at least $9.5 billion from at least $9.0 billion WOONSOCKET, R.I., May 6, 2026 /PRNewswire/ -- CVS Health Corporation (NYSE: CVS) today announced operating results for the three months ended March 31, 2026.

16.12.2025

Neutral

Final Trade: ETH, GM, CVS, NFLX

11.12.2025

Negative

The consumer is frustrated right now, says CVS Health CEO David Joyner

05.05.2026

CVS Caremark Expands Biosimilar Adoption Through Formulary Updates to Improve Affordability and Access

New changes expected to deliver significant client savings while maintaining rigorous clinical standards WOONSOCKET, R.I., May 5, 2026 /PRNewswire/ -- CVS Health (NYSE: CVS) today announced updates to its most common commercial template formularies that will expand the use of lower-cost biosimilars across multiple therapeutic categories, including changes effective July 1, 2026, that will prefer interchangeable biosimilars over select reference brands.

04.05.2026

Fathom Secures Strategic Investment From CVS Health Ventures to Accelerate Enterprise-Wide Autonomous Coding

SAN FRANCISCO--(BUSINESS WIRE)-- #AI--Fathom has received a strategic investment from CVS Health Ventures, the venture capital arm of CVS Health.

29.04.2026

Magic Molecule Expands to CVS Pharmacy®, Bringing FDA-Cleared Hypochlorous Acid Skincare to 6,000 Stores Nationwide

NEW YORK--(BUSINESS WIRE)--Magic Molecule, a leading hypochlorous acid-based skincare brand, today announced its expansion into pharmacy retail with the launch of its best-selling Daily Skin Spray at CVS Pharmacy® in 6,000 locations across the U.S. Magic Molecule Daily Skin Spray is FDA-cleared, and rigorously tested to meet the highest standards for quality, purity, and stability that never sacrifice performance, and are safe for all ages one month and up. Magic Molecule Daily Skin Spray suppo.

Search stocks

CVS Health Corporation (CVS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

CVS Health Corporation (CVS)

CVS Health (CVS) is a Top-Ranked Growth Stock: Should You Buy?

Here's Why CVS Health (CVS) is a Strong Value Stock

CVS Health: Still Cheap And Signs Of Improvement

CVS Health Q1 Earnings Call Highlights

CVS Health: Rapidly Improving Metrics And Promising Recovery Deserve Reiterated Buy Rating

These Analysts Increase Their Forecasts On CVS Health After Strong Q1 Results

CVS Health Q1 Earnings: We're (Finally) Back In Buy Territory

Videolar

Press-relizlar

CVS HEALTH CORPORATION REPORTS STRONG FIRST QUARTER 2026 RESULTS AND RAISES FULL-YEAR 2026 GUIDANCE

CVS Caremark Expands Biosimilar Adoption Through Formulary Updates to Improve Affordability and Access

Fathom Secures Strategic Investment From CVS Health Ventures to Accelerate Enterprise-Wide Autonomous Coding

Magic Molecule Expands to CVS Pharmacy®, Bringing FDA-Cleared Hypochlorous Acid Skincare to 6,000 Stores Nationwide